Antimicrobial part 4 Flashcards
Antiviral Drugs
♦Viruses are intracellular parasites
♦The do not have a cell wall or cell membrane and do not carry out metabolic processes
♦They use much of the metabolic processes of the host—very few drugs are selective enough to prevent viral
replication without injuring the infected individual
♦Treating viral illness is further complicated by the fact that symptoms appear late in the course of illness—after the virus has replicated—so drugs that prevent replication are not helpful
Treating Viral Respiratory Infections
♦Viral URIs that can be treated are Influenza A,
influenza B, and RSV
♦Flu vaccine is more effective than trying to treat
the patient after they are infected
♦Antivirals can be helpful when the patient
cannot be immunized OR when there is an
outbreak
Neuraminidase Inhibitors examples
Oseltamivir—Tamiflu prototype drug
Zanamivir—Relenza
Neuraminidase Inhibitors
Effective against flu A and B; they do not interfere with
immune response to the flu vaccines
Given prior to exposure, these agents prevent
infections and when given 24-48 hours after the
symptoms occur, they modestly decrease the intensity
and duration of the illness
Neuraminidase Inhibitors: MOA
• Flu viruses use a certain neuraminidase that it
slotted into the host cell membrane to release newly formed viruses; this enzyme is critical for the virus to live
• These drugs selectively inhibit neuraminidase—this
prevents new virions from being made and prevents
the virus from spreading
Neuraminidase Inhibitors: Pharmacokinetics
• Oseltamivir is dosed orally as a prodrug that is
hydrolyzed by the liver into active form
• Zanamivir is not active orally and is given via inhalation
• Both are eliminated unchanged in the urine
Neuraminidase Inhibitors: ADEs
• GI discomfort and nausea
• Symptoms are lessened if taken with food
• Irritation of the respiratory tract from Zanamivir—use
with caution in those with asthma or COPD—
because it can cause bronchospasm
Neuraminidase Inhibitors: Resistance
• Mutations of the neuraminidase enzyme
have been identified in adults with either of the
neuraminidase inhibitors
• These mutants are usually less infective and less
virulent than the wild type influenza
Amantadine Antivirals examples
♦Amantadine—Symmetrel [prototype]
♦Rimantadine—Lumazine
♦Spectrum is only Influenza A
♦Due to resistance—Amantadine is not recommended in the US
Ribavirin
Virazole; synthetic guanosine analog
Effective against a broad spectrum of RNA
and DNA viruses
Used in treatment of immunosuppressed
children with RSV
Also effective in chronic Hepatitis C infections
when used with other direct acting antivirals
[DAAs]
Ribavirin: MOA
• Inhibits replication of RNA and DNA viruses
Ribavirin: Pharmacokinetics
- Effective orally and by inhalation
- Aerosol is used to treat RSV
- Absorption is increased if the oral drug is taken with a fatty meal
- Drugs and metabolites are eliminated in the urine
Ribavirin: ADEs
- Ribavirin—dose dependent transient amnesia, elevated bilirubin
- Aerosol can be safer, but respiratory function in babies can deteriorate quickly after aerosol treatment is started— close monitoring is mandatory
- Ribavirin is contraindicated in pregnancy
Treating Hepatic Viral Infections
vMany different types of viral hepatitis—Hep B [DNA
virus] and Hep C [RNA virus] are the most
common cause of chronic Hep, cirrhosis and hepatocellular cancer
♦In 2019, we only have therapy for these two viral
hepatitis viruses
How is chronic Hep B treated
♦Chronic Hep B can be treated with Peginterferon-α-2a injected SQ weekly
♦Oral therapy for chronic Hep B can be with Lamivudine, Adefovir and Tenofovir
How is chronic hep C treated
♦with a combination of direct acting antivirals [DAAs]—based on the genotype of the virus that patient has ♦Ribavirin can be added to the DDAs to boost the viral response ♦Pegylated interferon is no longer commonly used for chronic Hep C
Treating Hepatis B—Interferons
-Naturally occurring inducible glycoproteins that interfere with virus to infect the host cells
-Interferons are synthesized by recombinant DNA
technology—α [alpha], ß [beta] and γ [gamma]
-In pegylated formulations—polyethylene glycol has been attached to interferon-α to increase the size of the molecule, and lengthens duration of action and reduces clearance
Hepatitis B—Interferons: MOA
• Incompletely understood
• Involves the induction of host cell enzymes that inhibit viral RNA translation—leading to the breakdown of
viral RNAs
Hepatitis B—Interferons: USES
• Peginterferon alfa-2a is approved for chronic Hep
B
• Also indicated for treatment of Hep C in combination with other drugs [but no longer common]
Hepatitis B—Interferons: ADEs
• Flu like sx—fever, chills, myalgias, arthralgias, Gi
distress
• Fatigue and mental depression is common
• Dose limiting BM toxicity, severe fatigue, weight loss,
somnolence, thyroiditis often curbs the use of this agent
• HF has been reported
Hepatitis B—Lamivudine
♦Epivir-HBV is a cytosine analog is an inhibitor of both Hep B and HIV reverse transcriptase
♦Must be phosphorylated by host enzymes to active
form
♦Competitively inhibits Hep B RNA-dependent DNA
polymerase
♦Intracellular half-life of the triphosphate is much longer
than its ½ life
♦Rate of HBV resistance is high after long term use—
therefore it is no longer 1st line in treating chronic Hep B
Hepatitis B—Adenovir
♦Hepsera is a nucleotide analog that is phosphorylated by cellular kinases to adefovir diphosphate, which is
incorporated into viral DNA
♦This causes termination of chain elongation and prevents replicationof Hep B virus
♦Given once daily; renally excreted via glomerular filtration and tubular secretion
♦Stopping the drug may result in an exacerbation of Hep B
♦Nephrotoxicity can occur with chronic use
♦Use with caution in those with CKD
♦No longer 1st line in treatment of Hep B—as it has lower efficacy than other agents
Hepatitis B—Entecavir
Baraclude is a guanosine nucleoside analog for the treatment of Hep B After intracellular phosphorylation to triphosphate, it competes with natural substrate, deoxyguanosine triphosphate, for viral reverse transcriptase Effective against lamivudine-resistant strains of Hep B; it is dosed once a day Excreted unchanged in the urine; adjustments are needed in those with CKD Avoid use of other agents with renal toxicity
Treatment of Hepatitis C
♦Once Hep C is inside the cell, a viral genome is released from the
nucleocapsid and a Hep C viral polyprotein is translated using the internal
ribosome entry site
♦Core NS3 and NS5a proteins form the replication complex on fat drops and
serve as a scaffold for RNA polymerase to reproduce the viral genome—
which is then packed in an envelope of glycoproteins before noncytolytic
secretion of mature virions
♦DAAs– target NS3/NS4A protease, NS5B polymerase and NS5A involved in
Hep C replication